Table 2.

Subgroup analyses for overall response at day 10 after treatment

	MTX cohort (Group A), %(95% CI)	Control cohort (Group B), %(95% CI)	P value
Diagnosis
AML/MDS	97.7(88.2- 99.6)	79.6 (67.1- 88.2)	0.011
ALL or others	97.0 (85.0- 99.4)	84.0 (65.3- 93.6)	0.075
Patient age
< 35	97.5 (87.1- 99.5)	80.4 (65.9- 89.7)	0.029
≥ 35	97.3 (86.5- 99.5)	81.6 (66.5- 90.7)	0.028
Patient gender
Male	100 (91.6- 100)	83.3 (69.3- 91.6)	0.012
Female	94.4 (81.8- 98.4)	78.3 (62.8- 88.6)	0.047
MAGIC criteria grade
I-II	100(95.0- 100)	85.9 (75.9- 92.1)	0.001
III-IV	50.0 (9.1- 90.8)	37.5 (10.2- 74.1)	0.57
GVHD risk category
Standard	100 (95.1- 100)	86.1 (76.2- 92.2)	0.001
High	33.3 (1.7- 87.4)	28.5 (5.1- 69.7)	0.70
GVHD organ involvement
Skin	97.1(90.2- 99.2)	86.1 (75.7- 92.5)	0.026
Maculopapular rash, < 25% of body surface	100	92.9
Maculopapular rash, 25%-50% of body surface	93.5	86.7
Maculopapular rash, > 50% of body surface	100	57.1
Lower GI and/or liver	87.5 (63.9- 96.5)	60.8 (40.7- 77.8)	0.070
Diarrhea. > 500 but < 1000 mL/d	100	81.8
Diarrhea > .1000 but < 1500 mL/d	50	50
Diarrhea > .1500 mL/d	0	0
bilirubin 2-3 mg/dL	-	40
Bilirubin 3.1–6 mg/dL	100	100
Graft source
PB	97.1(89.9- 99.1)	80.6 (69.1- 88.5)	0.003
BM	100 (65.5–100)	82.3 (55.8- 95.3)	0.23
Donor source
Matched sibling	100 (39.5–100)	50.0 (13.9- 86.0)	0.091
Haploidentical or unrelated	97.3 (90.6- 99.2)	83.5 (73.4- 90.3)	0.005
Center
Peking university	98.2 (90.8- 99.7)	83.0 (72.1- 90.2)	0.005
Others	95.0 (73.0- 99.7)	71.4 (42.0- 90.4)	0.079

Abbreviations: OR Odds ratio, HR Hazard ratios, CI Confidence interval, MAGIC Mount Sinai Acute GVHD International Consortium, GVHD Graft-versus-host disease, AML Acute myeloid leukemia, MDS Myelodysplastic syndrome, ALL Acute lymphoid leukemia, PB Peripheral blood, BM Bone marrow, GI Gastrointestinal tract